Huei-Mei Chen

Director, Gene Editing Sciences
MaxCyte, Inc.
Huei-Mei Chen is Director of Gene Editing Sciences at MaxCyte, Inc., where she leads scientific and strategic initiatives supporting cell and gene therapy development. She is experienced in advancing therapeutic programs from early research through preclinical and IND stages, including AAV-based gene therapies, Cas9-edited cell therapies, and in vivo base editing programs. Her expertise includes genomic safety, NGS assay development, genetic toxicology, and regulatory strategy.

Articles by Huei-Mei Chen

  • The Evolving Regulatory Landscape for Cell and Gene Therapies

    Thursday, October 29, 2026
    The regulatory landscape for CGTs is moving towards more explicit, risk-based assessment of intended editing outcomes, off-target activity, and genomic integrity. This evolution reflects both the promise of new editing technologies and the need to ...
  • <<
  • >>